 | • レポートコード：GIR-107A11847 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、143ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：産業機械＆装置 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、個別化医療・エピゲノミクスのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。個別化医療・エピゲノミクスの種類別市場規模（試薬、キット、機器、酵素、サービス）、用途別市場規模（腫瘍、非腫瘍、癌治療薬技術）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・個別化医療・エピゲノミクスの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Abbott Laboratories、Affymetrix、Agilent Technologies、Astellas Pharmaceuticals、BAYER AG、Bio Vision、Celgene Corp.、Emd Millipore、Epigenomics AG、Epigentex、Envivo Pharmaceuticals (Forum Pharmaceutricals)、Gilead Sciences、Glaxosmithkline、Illumina Inc.、Johnson & Johnson、Karus Therapeutics Limited、Laboratory Corp. Of America Holdings、LES Laboratoires Servier、Merck、Naturewise Biotech & Medicals Corp.、Novartis Pharma AG、Oncolys Biopharma Inc.、Orchid Chemicals & Pharmaceuticals Limited、Progen Pharmaceuticals Limited、Quest Diagnostics、Roche Holding AG、Rubicon Genomics、Takeda Pharmaceutical Company Limited ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：試薬、キット、機器、酵素、サービス ・用途別分析2016年-2026年：腫瘍、非腫瘍、癌治療薬技術 ・個別化医療・エピゲノミクスの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・個別化医療・エピゲノミクスのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・個別化医療・エピゲノミクスのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・個別化医療・エピゲノミクスの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・個別化医療・エピゲノミクスの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Personalized Medicine and Epigenomics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Personalized Medicine and Epigenomics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Personalized Medicine and Epigenomics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Personalized Medicine and Epigenomics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Reagents
Kits
Instruments
Enzymes
Services
Market segment by Application, can be divided into
Oncology
Non-Oncology
Cancer Drug Technology
Market segment by players, this report covers
Abbott Laboratories
Affymetrix
Agilent Technologies
Astellas Pharmaceuticals
BAYER AG
Bio Vision
Celgene Corp.
Emd Millipore
Epigenomics AG
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
Glaxosmithkline
Illumina Inc.
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
LES Laboratoires Servier
Merck
Naturewise Biotech & Medicals Corp.
Novartis Pharma AG
Oncolys Biopharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Personalized Medicine and Epigenomics
1.2 Classification of Personalized Medicine and Epigenomics by Type
1.2.1 Overview: Global Personalized Medicine and Epigenomics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Type in 2020
1.2.3 Reagents
1.2.4 Kits
1.2.5 Instruments
1.2.6 Enzymes
1.2.7 Services
1.3 Global Personalized Medicine and Epigenomics Market by Application
1.3.1 Overview: Global Personalized Medicine and Epigenomics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Oncology
1.3.3 Non-Oncology
1.3.4 Cancer Drug Technology
1.4 Global Personalized Medicine and Epigenomics Market Size & Forecast
1.5 Global Personalized Medicine and Epigenomics Market Size and Forecast by Region
1.5.1 Global Personalized Medicine and Epigenomics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Personalized Medicine and Epigenomics Market Size by Region, (2016-2021)
1.5.3 North America Personalized Medicine and Epigenomics Market Size and Prospect (2016-2026)
1.5.4 Europe Personalized Medicine and Epigenomics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Personalized Medicine and Epigenomics Market Size and Prospect (2016-2026)
1.5.6 South America Personalized Medicine and Epigenomics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Personalized Medicine and Epigenomics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Personalized Medicine and Epigenomics Market Drivers
1.6.2 Personalized Medicine and Epigenomics Market Restraints
1.6.3 Personalized Medicine and Epigenomics Trends Analysis
2 Company Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Product and Solutions
2.1.4 Abbott Laboratories Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Abbott Laboratories Recent Developments and Future Plans
2.2 Affymetrix
2.2.1 Affymetrix Details
2.2.2 Affymetrix Major Business
2.2.3 Affymetrix Personalized Medicine and Epigenomics Product and Solutions
2.2.4 Affymetrix Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Affymetrix Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Personalized Medicine and Epigenomics Product and Solutions
2.3.4 Agilent Technologies Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Astellas Pharmaceuticals
2.4.1 Astellas Pharmaceuticals Details
2.4.2 Astellas Pharmaceuticals Major Business
2.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product and Solutions
2.4.4 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Astellas Pharmaceuticals Recent Developments and Future Plans
2.5 BAYER AG
2.5.1 BAYER AG Details
2.5.2 BAYER AG Major Business
2.5.3 BAYER AG Personalized Medicine and Epigenomics Product and Solutions
2.5.4 BAYER AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 BAYER AG Recent Developments and Future Plans
2.6 Bio Vision
2.6.1 Bio Vision Details
2.6.2 Bio Vision Major Business
2.6.3 Bio Vision Personalized Medicine and Epigenomics Product and Solutions
2.6.4 Bio Vision Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Bio Vision Recent Developments and Future Plans
2.7 Celgene Corp.
2.7.1 Celgene Corp. Details
2.7.2 Celgene Corp. Major Business
2.7.3 Celgene Corp. Personalized Medicine and Epigenomics Product and Solutions
2.7.4 Celgene Corp. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Celgene Corp. Recent Developments and Future Plans
2.8 Emd Millipore
2.8.1 Emd Millipore Details
2.8.2 Emd Millipore Major Business
2.8.3 Emd Millipore Personalized Medicine and Epigenomics Product and Solutions
2.8.4 Emd Millipore Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Emd Millipore Recent Developments and Future Plans
2.9 Epigenomics AG
2.9.1 Epigenomics AG Details
2.9.2 Epigenomics AG Major Business
2.9.3 Epigenomics AG Personalized Medicine and Epigenomics Product and Solutions
2.9.4 Epigenomics AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Epigenomics AG Recent Developments and Future Plans
2.10 Epigentex
2.10.1 Epigentex Details
2.10.2 Epigentex Major Business
2.10.3 Epigentex Personalized Medicine and Epigenomics Product and Solutions
2.10.4 Epigentex Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Epigentex Recent Developments and Future Plans
2.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
2.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Details
2.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Major Business
2.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product and Solutions
2.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Developments and Future Plans
2.12 Gilead Sciences
2.12.1 Gilead Sciences Details
2.12.2 Gilead Sciences Major Business
2.12.3 Gilead Sciences Personalized Medicine and Epigenomics Product and Solutions
2.12.4 Gilead Sciences Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Gilead Sciences Recent Developments and Future Plans
2.13 Glaxosmithkline
2.13.1 Glaxosmithkline Details
2.13.2 Glaxosmithkline Major Business
2.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Product and Solutions
2.13.4 Glaxosmithkline Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Glaxosmithkline Recent Developments and Future Plans
2.14 Illumina Inc.
2.14.1 Illumina Inc. Details
2.14.2 Illumina Inc. Major Business
2.14.3 Illumina Inc. Personalized Medicine and Epigenomics Product and Solutions
2.14.4 Illumina Inc. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Illumina Inc. Recent Developments and Future Plans
2.15 Johnson & Johnson
2.15.1 Johnson & Johnson Details
2.15.2 Johnson & Johnson Major Business
2.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Product and Solutions
2.15.4 Johnson & Johnson Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Johnson & Johnson Recent Developments and Future Plans
2.16 Karus Therapeutics Limited
2.16.1 Karus Therapeutics Limited Details
2.16.2 Karus Therapeutics Limited Major Business
2.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Product and Solutions
2.16.4 Karus Therapeutics Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Karus Therapeutics Limited Recent Developments and Future Plans
2.17 Laboratory Corp. Of America Holdings
2.17.1 Laboratory Corp. Of America Holdings Details
2.17.2 Laboratory Corp. Of America Holdings Major Business
2.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product and Solutions
2.17.4 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Laboratory Corp. Of America Holdings Recent Developments and Future Plans
2.18 LES Laboratoires Servier
2.18.1 LES Laboratoires Servier Details
2.18.2 LES Laboratoires Servier Major Business
2.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Product and Solutions
2.18.4 LES Laboratoires Servier Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 LES Laboratoires Servier Recent Developments and Future Plans
2.19 Merck
2.19.1 Merck Details
2.19.2 Merck Major Business
2.19.3 Merck Personalized Medicine and Epigenomics Product and Solutions
2.19.4 Merck Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Merck Recent Developments and Future Plans
2.20 Naturewise Biotech & Medicals Corp.
2.20.1 Naturewise Biotech & Medicals Corp. Details
2.20.2 Naturewise Biotech & Medicals Corp. Major Business
2.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product and Solutions
2.20.4 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Naturewise Biotech & Medicals Corp. Recent Developments and Future Plans
2.21 Novartis Pharma AG
2.21.1 Novartis Pharma AG Details
2.21.2 Novartis Pharma AG Major Business
2.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Product and Solutions
2.21.4 Novartis Pharma AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Novartis Pharma AG Recent Developments and Future Plans
2.22 Oncolys Biopharma Inc.
2.22.1 Oncolys Biopharma Inc. Details
2.22.2 Oncolys Biopharma Inc. Major Business
2.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product and Solutions
2.22.4 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.22.5 Oncolys Biopharma Inc. Recent Developments and Future Plans
2.23 Orchid Chemicals & Pharmaceuticals Limited
2.23.1 Orchid Chemicals & Pharmaceuticals Limited Details
2.23.2 Orchid Chemicals & Pharmaceuticals Limited Major Business
2.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product and Solutions
2.23.4 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Developments and Future Plans
2.24 Progen Pharmaceuticals Limited
2.24.1 Progen Pharmaceuticals Limited Details
2.24.2 Progen Pharmaceuticals Limited Major Business
2.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product and Solutions
2.24.4 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.24.5 Progen Pharmaceuticals Limited Recent Developments and Future Plans
2.25 Quest Diagnostics
2.25.1 Quest Diagnostics Details
2.25.2 Quest Diagnostics Major Business
2.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Product and Solutions
2.25.4 Quest Diagnostics Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.25.5 Quest Diagnostics Recent Developments and Future Plans
2.26 Roche Holding AG
2.26.1 Roche Holding AG Details
2.26.2 Roche Holding AG Major Business
2.26.3 Roche Holding AG Personalized Medicine and Epigenomics Product and Solutions
2.26.4 Roche Holding AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.26.5 Roche Holding AG Recent Developments and Future Plans
2.27 Rubicon Genomics
2.27.1 Rubicon Genomics Details
2.27.2 Rubicon Genomics Major Business
2.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Product and Solutions
2.27.4 Rubicon Genomics Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.27.5 Rubicon Genomics Recent Developments and Future Plans
2.28 Takeda Pharmaceutical Company Limited
2.28.1 Takeda Pharmaceutical Company Limited Details
2.28.2 Takeda Pharmaceutical Company Limited Major Business
2.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product and Solutions
2.28.4 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2021)
2.28.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Personalized Medicine and Epigenomics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Personalized Medicine and Epigenomics Players Market Share
3.2.2 Top 10 Personalized Medicine and Epigenomics Players Market Share
3.2.3 Market Competition Trend
3.3 Personalized Medicine and Epigenomics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Personalized Medicine and Epigenomics Revenue and Market Share by Type (2016-2021)
4.2 Global Personalized Medicine and Epigenomics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2016-2021)
5.2 Personalized Medicine and Epigenomics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Personalized Medicine and Epigenomics Revenue by Type (2016-2026)
6.2 North America Personalized Medicine and Epigenomics Revenue by Application (2016-2026)
6.3 North America Personalized Medicine and Epigenomics Market Size by Country
6.3.1 North America Personalized Medicine and Epigenomics Revenue by Country (2016-2026)
6.3.2 United States Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
6.3.3 Canada Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
6.3.4 Mexico Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Personalized Medicine and Epigenomics Revenue by Type (2016-2026)
7.2 Europe Personalized Medicine and Epigenomics Revenue by Application (2016-2026)
7.3 Europe Personalized Medicine and Epigenomics Market Size by Country
7.3.1 Europe Personalized Medicine and Epigenomics Revenue by Country (2016-2026)
7.3.2 Germany Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
7.3.3 France Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
7.3.5 Russia Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
7.3.6 Italy Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Personalized Medicine and Epigenomics Revenue by Type (2016-2026)
8.2 Asia-Pacific Personalized Medicine and Epigenomics Revenue by Application (2016-2026)
8.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region
8.3.1 Asia-Pacific Personalized Medicine and Epigenomics Revenue by Region (2016-2026)
8.3.2 China Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
8.3.3 Japan Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
8.3.4 South Korea Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
8.3.5 India Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
8.3.7 Australia Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Personalized Medicine and Epigenomics Revenue by Type (2016-2026)
9.2 South America Personalized Medicine and Epigenomics Revenue by Application (2016-2026)
9.3 South America Personalized Medicine and Epigenomics Market Size by Country
9.3.1 South America Personalized Medicine and Epigenomics Revenue by Country (2016-2026)
9.3.2 Brazil Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
9.3.3 Argentina Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Personalized Medicine and Epigenomics Revenue by Type (2016-2026)
10.2 Middle East & Africa Personalized Medicine and Epigenomics Revenue by Application (2016-2026)
10.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country
10.3.1 Middle East & Africa Personalized Medicine and Epigenomics Revenue by Country (2016-2026)
10.3.2 Turkey Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
10.3.4 UAE Personalized Medicine and Epigenomics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Personalized Medicine and Epigenomics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Personalized Medicine and Epigenomics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Personalized Medicine and Epigenomics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Personalized Medicine and Epigenomics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Personalized Medicine and Epigenomics Revenue Market Share by Region (2021-2026)
Table 6. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 7. Abbott Laboratories Major Business
Table 8. Abbott Laboratories Personalized Medicine and Epigenomics Product and Solutions
Table 9. Abbott Laboratories Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Affymetrix Corporate Information, Head Office, and Major Competitors
Table 11. Affymetrix Major Business
Table 12. Affymetrix Personalized Medicine and Epigenomics Product and Solutions
Table 13. Affymetrix Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Agilent Technologies Corporate Information, Head Office, and Major Competitors
Table 15. Agilent Technologies Major Business
Table 16. Agilent Technologies Personalized Medicine and Epigenomics Product and Solutions
Table 17. Agilent Technologies Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Astellas Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 19. Astellas Pharmaceuticals Major Business
Table 20. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product and Solutions
Table 21. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. BAYER AG Corporate Information, Head Office, and Major Competitors
Table 23. BAYER AG Major Business
Table 24. BAYER AG Personalized Medicine and Epigenomics Product and Solutions
Table 25. BAYER AG Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Bio Vision Corporate Information, Head Office, and Major Competitors
Table 27. Bio Vision Major Business
Table 28. Bio Vision Personalized Medicine and Epigenomics Product and Solutions
Table 29. Bio Vision Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Celgene Corp. Corporate Information, Head Office, and Major Competitors
Table 31. Celgene Corp. Major Business
Table 32. Celgene Corp. Personalized Medicine and Epigenomics Product and Solutions
Table 33. Celgene Corp. Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Emd Millipore Corporate Information, Head Office, and Major Competitors
Table 35. Emd Millipore Major Business
Table 36. Emd Millipore Personalized Medicine and Epigenomics Product and Solutions
Table 37. Emd Millipore Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Epigenomics AG Corporate Information, Head Office, and Major Competitors
Table 39. Epigenomics AG Major Business
Table 40. Epigenomics AG Personalized Medicine and Epigenomics Product and Solutions
Table 41. Epigenomics AG Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Epigentex Corporate Information, Head Office, and Major Competitors
Table 43. Epigentex Major Business
Table 44. Epigentex Personalized Medicine and Epigenomics Product and Solutions
Table 45. Epigentex Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Envivo Pharmaceuticals (Forum Pharmaceutricals) Corporate Information, Head Office, and Major Competitors
Table 47. Envivo Pharmaceuticals (Forum Pharmaceutricals) Major Business
Table 48. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product and Solutions
Table 49. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Gilead Sciences Corporate Information, Head Office, and Major Competitors
Table 51. Gilead Sciences Major Business
Table 52. Gilead Sciences Personalized Medicine and Epigenomics Product and Solutions
Table 53. Gilead Sciences Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Glaxosmithkline Corporate Information, Head Office, and Major Competitors
Table 55. Glaxosmithkline Major Business
Table 56. Glaxosmithkline Personalized Medicine and Epigenomics Product and Solutions
Table 57. Glaxosmithkline Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Illumina Inc. Corporate Information, Head Office, and Major Competitors
Table 59. Illumina Inc. Major Business
Table 60. Illumina Inc. Personalized Medicine and Epigenomics Product and Solutions
Table 61. Illumina Inc. Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 63. Johnson & Johnson Major Business
Table 64. Johnson & Johnson Personalized Medicine and Epigenomics Product and Solutions
Table 65. Johnson & Johnson Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Karus Therapeutics Limited Corporate Information, Head Office, and Major Competitors
Table 67. Karus Therapeutics Limited Major Business
Table 68. Karus Therapeutics Limited Personalized Medicine and Epigenomics Product and Solutions
Table 69. Karus Therapeutics Limited Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Laboratory Corp. Of America Holdings Corporate Information, Head Office, and Major Competitors
Table 71. Laboratory Corp. Of America Holdings Major Business
Table 72. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product and Solutions
Table 73. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. LES Laboratoires Servier Corporate Information, Head Office, and Major Competitors
Table 75. LES Laboratoires Servier Major Business
Table 76. LES Laboratoires Servier Personalized Medicine and Epigenomics Product and Solutions
Table 77. LES Laboratoires Servier Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Merck Corporate Information, Head Office, and Major Competitors
Table 79. Merck Major Business
Table 80. Merck Personalized Medicine and Epigenomics Product and Solutions
Table 81. Merck Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Naturewise Biotech & Medicals Corp. Corporate Information, Head Office, and Major Competitors
Table 83. Naturewise Biotech & Medicals Corp. Major Business
Table 84. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product and Solutions
Table 85. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Novartis Pharma AG Corporate Information, Head Office, and Major Competitors
Table 87. Novartis Pharma AG Major Business
Table 88. Novartis Pharma AG Personalized Medicine and Epigenomics Product and Solutions
Table 89. Novartis Pharma AG Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. Oncolys Biopharma Inc. Corporate Information, Head Office, and Major Competitors
Table 91. Oncolys Biopharma Inc. Major Business
Table 92. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product and Solutions
Table 93. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 94. Orchid Chemicals & Pharmaceuticals Limited Corporate Information, Head Office, and Major Competitors
Table 95. Orchid Chemicals & Pharmaceuticals Limited Major Business
Table 96. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product and Solutions
Table 97. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 98. Progen Pharmaceuticals Limited Corporate Information, Head Office, and Major Competitors
Table 99. Progen Pharmaceuticals Limited Major Business
Table 100. Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product and Solutions
Table 101. Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 102. Quest Diagnostics Corporate Information, Head Office, and Major Competitors
Table 103. Quest Diagnostics Major Business
Table 104. Quest Diagnostics Personalized Medicine and Epigenomics Product and Solutions
Table 105. Quest Diagnostics Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 106. Roche Holding AG Corporate Information, Head Office, and Major Competitors
Table 107. Roche Holding AG Major Business
Table 108. Roche Holding AG Personalized Medicine and Epigenomics Product and Solutions
Table 109. Roche Holding AG Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 110. Rubicon Genomics Corporate Information, Head Office, and Major Competitors
Table 111. Rubicon Genomics Major Business
Table 112. Rubicon Genomics Personalized Medicine and Epigenomics Product and Solutions
Table 113. Rubicon Genomics Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 114. Takeda Pharmaceutical Company Limited Corporate Information, Head Office, and Major Competitors
Table 115. Takeda Pharmaceutical Company Limited Major Business
Table 116. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product and Solutions
Table 117. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 118. Global Personalized Medicine and Epigenomics Revenue (USD Million) by Players (2019-2021)
Table 119. Global Personalized Medicine and Epigenomics Revenue Share by Players (2019-2021)
Table 120. Breakdown of Personalized Medicine and Epigenomics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 121. Personalized Medicine and Epigenomics Players Head Office, Products and Services Provided
Table 122. Personalized Medicine and Epigenomics Mergers & Acquisitions in the Past Five Years
Table 123. Personalized Medicine and Epigenomics New Entrants and Expansion Plans
Table 124. Global Personalized Medicine and Epigenomics Revenue (USD Million) by Type (2016-2021)
Table 125. Global Personalized Medicine and Epigenomics Revenue Share by Type (2016-2021)
Table 126. Global Personalized Medicine and Epigenomics Revenue Forecast by Type (2021-2026)
Table 127. Global Personalized Medicine and Epigenomics Revenue by Application (2016-2021)
Table 128. Global Personalized Medicine and Epigenomics Revenue Forecast by Application (2021-2026)
Table 129. North America Personalized Medicine and Epigenomics Revenue by Type (2016-2021) & (USD Million)
Table 130. North America Personalized Medicine and Epigenomics Revenue by Type (2021-2026) & (USD Million)
Table 131. North America Personalized Medicine and Epigenomics Revenue by Application (2016-2021) & (USD Million)
Table 132. North America Personalized Medicine and Epigenomics Revenue by Application (2021-2026) & (USD Million)
Table 133. North America Personalized Medicine and Epigenomics Revenue by Country (2016-2021) & (USD Million)
Table 134. North America Personalized Medicine and Epigenomics Revenue by Country (2021-2026) & (USD Million)
Table 135. Europe Personalized Medicine and Epigenomics Revenue by Type (2016-2021) & (USD Million)
Table 136. Europe Personalized Medicine and Epigenomics Revenue by Type (2021-2026) & (USD Million)
Table 137. Europe Personalized Medicine and Epigenomics Revenue by Application (2016-2021) & (USD Million)
Table 138. Europe Personalized Medicine and Epigenomics Revenue by Application (2021-2026) & (USD Million)
Table 139. Europe Personalized Medicine and Epigenomics Revenue by Country (2016-2021) & (USD Million)
Table 140. Europe Personalized Medicine and Epigenomics Revenue by Country (2021-2026) & (USD Million)
Table 141. Asia-Pacific Personalized Medicine and Epigenomics Revenue by Type (2016-2021) & (USD Million)
Table 142. Asia-Pacific Personalized Medicine and Epigenomics Revenue by Type (2021-2026) & (USD Million)
Table 143. Asia-Pacific Personalized Medicine and Epigenomics Revenue by Application (2016-2021) & (USD Million)
Table 144. Asia-Pacific Personalized Medicine and Epigenomics Revenue by Application (2021-2026) & (USD Million)
Table 145. Asia-Pacific Personalized Medicine and Epigenomics Revenue by Region (2016-2021) & (USD Million)
Table 146. Asia-Pacific Personalized Medicine and Epigenomics Revenue by Region (2021-2026) & (USD Million)
Table 147. South America Personalized Medicine and Epigenomics Revenue by Type (2016-2021) & (USD Million)
Table 148. South America Personalized Medicine and Epigenomics Revenue by Type (2021-2026) & (USD Million)
Table 149. South America Personalized Medicine and Epigenomics Revenue by Application (2016-2021) & (USD Million)
Table 150. South America Personalized Medicine and Epigenomics Revenue by Application (2021-2026) & (USD Million)
Table 151. South America Personalized Medicine and Epigenomics Revenue by Country (2016-2021) & (USD Million)
Table 152. South America Personalized Medicine and Epigenomics Revenue by Country (2021-2026) & (USD Million)
Table 153. Middle East & Africa Personalized Medicine and Epigenomics Revenue by Type (2016-2021) & (USD Million)
Table 154. Middle East & Africa Personalized Medicine and Epigenomics Revenue by Type (2021-2026) & (USD Million)
Table 155. Middle East & Africa Personalized Medicine and Epigenomics Revenue by Application (2016-2021) & (USD Million)
Table 156. Middle East & Africa Personalized Medicine and Epigenomics Revenue by Application (2021-2026) & (USD Million)
Table 157. Middle East & Africa Personalized Medicine and Epigenomics Revenue by Country (2016-2021) & (USD Million)
Table 158. Middle East & Africa Personalized Medicine and Epigenomics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Personalized Medicine and Epigenomics Picture
Figure 2. Global Personalized Medicine and Epigenomics Revenue Market Share by Type in 2020
Figure 3. Reagents
Figure 4. Kits
Figure 5. Instruments
Figure 6. Enzymes
Figure 7. Services
Figure 8. Personalized Medicine and Epigenomics Revenue Market Share by Application in 2020
Figure 9. Oncology Picture
Figure 10. Non-Oncology Picture
Figure 11. Cancer Drug Technology Picture
Figure 12. Global Personalized Medicine and Epigenomics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Personalized Medicine and Epigenomics Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Personalized Medicine and Epigenomics Revenue Market Share by Region (2016-2026)
Figure 15. Global Personalized Medicine and Epigenomics Revenue Market Share by Region in 2020
Figure 16. North America Personalized Medicine and Epigenomics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Personalized Medicine and Epigenomics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Personalized Medicine and Epigenomics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Personalized Medicine and Epigenomics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Personalized Medicine and Epigenomics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Personalized Medicine and Epigenomics Market Drivers
Figure 22. Personalized Medicine and Epigenomics Market Restraints
Figure 23. Personalized Medicine and Epigenomics Market Trends
Figure 24. Abbott Laboratories Recent Developments and Future Plans
Figure 25. Affymetrix Recent Developments and Future Plans
Figure 26. Agilent Technologies Recent Developments and Future Plans
Figure 27. Astellas Pharmaceuticals Recent Developments and Future Plans
Figure 28. BAYER AG Recent Developments and Future Plans
Figure 29. Bio Vision Recent Developments and Future Plans
Figure 30. Celgene Corp. Recent Developments and Future Plans
Figure 31. Emd Millipore Recent Developments and Future Plans
Figure 32. Epigenomics AG Recent Developments and Future Plans
Figure 33. Epigentex Recent Developments and Future Plans
Figure 34. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Developments and Future Plans
Figure 35. Gilead Sciences Recent Developments and Future Plans
Figure 36. Glaxosmithkline Recent Developments and Future Plans
Figure 37. Illumina Inc. Recent Developments and Future Plans
Figure 38. Johnson & Johnson Recent Developments and Future Plans
Figure 39. Karus Therapeutics Limited Recent Developments and Future Plans
Figure 40. Laboratory Corp. Of America Holdings Recent Developments and Future Plans
Figure 41. LES Laboratoires Servier Recent Developments and Future Plans
Figure 42. Merck Recent Developments and Future Plans
Figure 43. Naturewise Biotech & Medicals Corp. Recent Developments and Future Plans
Figure 44. Novartis Pharma AG Recent Developments and Future Plans
Figure 45. Oncolys Biopharma Inc. Recent Developments and Future Plans
Figure 46. Orchid Chemicals & Pharmaceuticals Limited Recent Developments and Future Plans
Figure 47. Progen Pharmaceuticals Limited Recent Developments and Future Plans
Figure 48. Quest Diagnostics Recent Developments and Future Plans
Figure 49. Roche Holding AG Recent Developments and Future Plans
Figure 50. Rubicon Genomics Recent Developments and Future Plans
Figure 51. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
Figure 52. Global Personalized Medicine and Epigenomics Revenue Share by Players in 2020
Figure 53. Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 54. Global Top 3 Players Personalized Medicine and Epigenomics Revenue Market Share in 2020
Figure 55. Global Top 10 Players Personalized Medicine and Epigenomics Revenue Market Share in 2020
Figure 56. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 57. Global Personalized Medicine and Epigenomics Revenue Share by Type in 2020
Figure 58. Global Personalized Medicine and Epigenomics Market Share Forecast by Type (2021-2026)
Figure 59. Global Personalized Medicine and Epigenomics Revenue Share by Application in 2020
Figure 60. Global Personalized Medicine and Epigenomics Market Share Forecast by Application (2021-2026)
Figure 61. North America Personalized Medicine and Epigenomics Sales Market Share by Type (2016-2026)
Figure 62. North America Personalized Medicine and Epigenomics Sales Market Share by Application (2016-2026)
Figure 63. North America Personalized Medicine and Epigenomics Revenue Market Share by Country (2016-2026)
Figure 64. United States Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Canada Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Mexico Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Europe Personalized Medicine and Epigenomics Sales Market Share by Type (2016-2026)
Figure 68. Europe Personalized Medicine and Epigenomics Sales Market Share by Application (2016-2026)
Figure 69. Europe Personalized Medicine and Epigenomics Revenue Market Share by Country (2016-2026)
Figure 70. Germany Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. France Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. United Kingdom Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Russia Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Italy Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Asia-Pacific Personalized Medicine and Epigenomics Sales Market Share by Type (2016-2026)
Figure 76. Asia-Pacific Personalized Medicine and Epigenomics Sales Market Share by Application (2016-2026)
Figure 77. Asia-Pacific Personalized Medicine and Epigenomics Revenue Market Share by Region (2016-2026)
Figure 78. China Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Japan Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. South Korea Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. India Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. Southeast Asia Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Australia Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. South America Personalized Medicine and Epigenomics Sales Market Share by Type (2016-2026)
Figure 85. South America Personalized Medicine and Epigenomics Sales Market Share by Application (2016-2026)
Figure 86. South America Personalized Medicine and Epigenomics Revenue Market Share by Country (2016-2026)
Figure 87. Brazil Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 88. Argentina Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 89. Middle East and Africa Personalized Medicine and Epigenomics Sales Market Share by Type (2016-2026)
Figure 90. Middle East and Africa Personalized Medicine and Epigenomics Sales Market Share by Application (2016-2026)
Figure 91. Middle East and Africa Personalized Medicine and Epigenomics Revenue Market Share by Country (2016-2026)
Figure 92. Turkey Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 93. Saudi Arabia Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 94. UAE Personalized Medicine and Epigenomics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 95. Methodology
Figure 96. Research Process and Data Source
世界のオーダメイド医療およびエピゲノミクス市場予測（～2024年）：企業別、地域別、種類・用途別 Epigenomics is the study of the complete set of epigenetic modifications on the genetic material of a cell, known as the epigenome. The field is analogous to genomics and proteomics, which are the study of the genome and proteome of a cell. Scope of the Report: The global Personalized Medicine and E…- 世界のパーソナライズ癌医学市場予測（～2024年） Personalized medicine is at an early stage of development. Scientists found that some cancer cells have particular proteins in the cell and others don’t. Sometimes, cancer cells have far more of a particular protein than healthy cells. Genetic testing of cancer cells and normal cells helps doctors c…
- 世界のオーダメイド医療市場予測（～2024年）：企業別、地域別、種類・用途別 Individualized medication, medication "vary from person to person" , give full consideration to each patient's genetic factors, gender, age, body weight, physiological and pathological characteristics, and are taking other drugs on the basis of the comprehensive situation of safe, reasonable, effect…
- 世界の個別化小売栄養＆健康市場 2021：企業別、地域別、種類・用途別 The Personalized Retail Nutrition & Wellness market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizati…
- パーソナライズ型パッケージ市場：世界及び中国市場分析・予測（～2024年） Personalized Packaging Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Personalized Packaging industry with a focus on the Chinese market. The report provides key statistics on the market status of the Personalized Packaging m…